InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-62.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by LEDERMAN SETH, Chairman & CEO. Insider active across 1 company, notably Tonix Pharmaceuticals Holding Corp.. Cumulatively, 6 disclosures have been logged. Split: 5 buys · 0 sell. Total volume traded: €145k. History available since 28 September 2021. The latest transaction was filed on 15 May 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations6 total
4,000 shares@ US$21.5553.3% of flowCommon Stock, $0.001 par valueSEC:0001999371-25-006261:0
Ideal exit: 9 Feb 2026 (T+270)
5.18 shares@ US$3.380.0% of flowCommon Stock, $0.001 par valueSEC:0001839882-25-011952:0
20,000 shares@ US$1.710.013% mcap48.5% of flowCommon Stock, $0.001 par valueSEC:0001387131-22-007441:0
Ideal exit: 26 Mar 2023 (T+270)
100,000 shares@ US$0.2450.0089% mcap33.0% of flowCommon Stock, $0.001 par valueSEC:0001387131-22-003991:0
Ideal exit: 20 Dec 2022 (T+270)
12,000 shares@ US$0.610.0025% mcap9.3% of flowCommon Stock, $0.001 par valueSEC:0001387131-21-009696:0
Ideal exit: 25 Jun 2022 (T+270)
12,000 shares@ US$0.614.3% of flowCommon Stock, $0.001 par valueSEC:0001387131-21-009696
Ideal exit: 25 Jun 2022 (T+270)
6 of 6 declarations
About LEDERMAN SETH
Seth Lederman is the Chief Executive Officer of Tonix Pharmaceuticals Holding Corp. He leads the company by overseeing its operations and developing strategies for innovation in the biopharmaceutical sector. His leadership is crucial for Tonix's growth.
